G 2/21: how to support inventive steps in patentability

Post-published evidence can be crucial to establishing patentability. G 2/21, the European Patent Office (EPO)’s referral to the Enlarged Board of Appeal (EBA) on the question of whether post-published evidence can be used to support the concept of “inventive step”.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

CRISPR: the shifting sands of patentability

12 November 2015 The patentability of any claims directed to the use of CRISPR technology in human embryo-like structures and human reproductive cells is far from certain, as Duncan Ribbons and Maeve Lynch of Redd explain.

Americas

Europe v US: the patentability of diagnostic claims

17 September 2015 Researchers should keep in mind that broad claims applying the discovery of a biomarker and disease correlation are currently patentable in Europe but not in the US. Andrew Carridge and Neil Thornton of Reddie & Grose report.

More features

Killing the golden goose of US drug innovation (Part I): Follow the money

GSK escalates mRNA COVID-19 vaccine dispute

The flaw that landed Sanofi a win in the rare disease space

An update on patenting in Ukraine, Russia and Eurasia

The rise of pro-NPE and patent sentiment in the US

UPC sees rising small molecule litigation with Pfizer in the hot seat

Why the Caribbean cannabis economy is ripe for IP protection

The right formula: Minimising the cost of chemical and pharma patents

G 2/21: how to support inventive steps in patentability

More on this story

Editor's picks

Editor's picks

More features